132 related articles for article (PubMed ID: 33037681)
1. Intracellular vincristine levels in lymphoblasts affect treatment outcome in childhood B-lymphoblastic leukaemia: Ma-Spore ALL 2010 study.
Jiang N; Wang L; Xiang X; Li Z; Chiew EKH; Koo YM; Lee HS; Lin HP; Tan AM; Quah TC; Kham SKY; Goh BC; Ariffin H; Yeoh AE
Br J Clin Pharmacol; 2021 Apr; 87(4):1990-1999. PubMed ID: 33037681
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
[TBL] [Abstract][Full Text] [Related]
3. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS
Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807
[TBL] [Abstract][Full Text] [Related]
4. Vincristine disposition in children with acute lymphoblastic leukemia.
de Graaf SS; Bloemhof H; Vendrig DE; Uges DR
Med Pediatr Oncol; 1995 Apr; 24(4):235-40. PubMed ID: 7700168
[TBL] [Abstract][Full Text] [Related]
5. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG).
Groninger E; Meeuwsen-de Boer T; Koopmans P; Uges D; Sluiter W; Veerman A; Kamps W; de Graaf S
Eur J Cancer; 2005 Jan; 41(1):98-103. PubMed ID: 15617994
[TBL] [Abstract][Full Text] [Related]
6. Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species?
Groninger E; Meeuwsen-De Boer GJ; De Graaf SS; Kamps WA; De Bont ES
Int J Oncol; 2002 Dec; 21(6):1339-45. PubMed ID: 12429986
[TBL] [Abstract][Full Text] [Related]
7. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and bcl-2 expression in acute lymphoblastic leukaemia and non-Hodgkin's lymphoma in children.
Pituch-Noworolska A; Hajto B; Balwierz W; Klus K
Haematologia (Budap); 2001; 31(3):191-207. PubMed ID: 11855781
[TBL] [Abstract][Full Text] [Related]
11. The effect of increased lipoproteins levels on the disposition of vincristine in rat.
Khalil HA; Belal TS; El-Yazbi AF; Hamdy DA
Lipids Health Dis; 2016 Sep; 15(1):152. PubMed ID: 27613245
[TBL] [Abstract][Full Text] [Related]
12. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
13. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
14. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
15. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.
Li Z; Lee SHR; Chin WHN; Lu Y; Jiang N; Lim EH; Coustan-Smith E; Chiew KH; Oh BLZ; Koh GS; Chen Z; Kham SKY; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
Blood Adv; 2021 Dec; 5(23):5226-5238. PubMed ID: 34547766
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous quantification and pharmacokinetics of vincristine and its major metabolite M1 in Chinese pediatric ALL patients by LC-MS/MS.
Yuan Y; Chen C; You G; Yao R; Zhu X; Wu X; Wu J; Zhao W; Li Z; Zhang S
J Pharm Biomed Anal; 2023 Sep; 234():115578. PubMed ID: 37459833
[TBL] [Abstract][Full Text] [Related]
17. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A; Inukai T; Kagami K; Abe M; Takagi M; Fukushima T; Fukushima H; Nanmoku T; Terui K; Ito T; Toki T; Ito E; Fujimura J; Goto H; Endo M; Look T; Kamps M; Minegishi M; Takita J; Inaba T; Takahashi H; Ohara A; Harama D; Shinohara T; Somazu S; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2019 Sep; 8(11):5274-5288. PubMed ID: 31305009
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of heme oxygenase-1 in microenvironment mediates vincristine resistance of B-cell acute lymphoblastic leukemia by promoting vascular endothelial growth factor secretion.
Yu K; Wang J; Lu T; Ma D; Wei D; Guo Y; Cheng B; Wang W; Fang Q
J Cell Biochem; 2019 Oct; 120(10):17791-17810. PubMed ID: 31264739
[TBL] [Abstract][Full Text] [Related]
19. CD38-Directed Vincristine Nanotherapy for Acute Lymphoblastic Leukemia.
Zhang Y; An J; Shao Y; Yu N; Yue S; Sun H; Zhang J; Gu W; Xia Y; Zhang J; Xu Y; Zhong Z
Biomacromolecules; 2022 Jan; 23(1):377-387. PubMed ID: 34913676
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration.
Kellie SJ; Barbaric D; Koopmans P; Earl J; Carr DJ; de Graaf SS
Cancer; 2002 Mar; 94(6):1815-20. PubMed ID: 11920545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
